» COVID-19 Information


Manage your account, request prescriptions, set up appointments & more.

Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label



Clinical Trial Title

Study of Blood Samples From Newborns With Down Syndrome

Trial Status

Closed to Enrollment

Start Date

January 31, 2011

Trial Type

Pediatric Cancer (Oncology)

Specific Condition

Transient Myeloproliferative Disorder (TMD)


ATIONALE: Studying the genes expressed in samples of blood from patients with Down syndrome may help doctors identify biomarkers related to cancer.

PURPOSE: This research study is looking at blood samples from newborns with Down syndrome.

Eligibility Criteria

Age: <90 days of age at diagnosis of Transient Myeloproliferative Disorder (TMD)
Diagnosis of TMD defined as:

  • a diagnosis of Down syndrome or Down syndrome mosaicism AND
  • non-erythroid and non-lymphoid blast (any amount) in the peripheral blood verified with second sample OR

Trisomy 21 positive leukemic blasts documented by biopsy of any organ (including >5% non-erythroid/non-lymphoid blasts documented by bone marrow aspirate or biopsy). Infants with isolated trisomy 21 positivity identified only in the leukemic blasts are eligible for study

Enrollment must take place within 21 days following the diagnosis of TMD by a pediatric hematology/oncology specialist



Study status is:
Active, not recruiting: The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.

Principal Investigator Name

Janice Olson, MD

Contact Name

Children's Cancer and Blood Disorders Program


(503) 276-9300

Last Updated: Wednesday, January 27, 2021 11:41:08 AM